Introduction
============

With significantly improved quality of life and long-term survival, liver transplantation remains the effective treatment for benign end-stage liver diseases and some of the selected liver malignant tumors.[@b1-tcrm-13-675] Intestinal perforation, which has an incidence of 1% to 5.3%, is a rare complication after liver transplantation. Some of the factors including abdominal surgery history, prolonged portal vein occlusion time, inadequacy of portal venous collateral circulation, long-term use of corticosteroids, and antirejection drugs were reported to be related to intestinal perforation; however, there is no definitive evidence.[@b2-tcrm-13-675] We started liver transplantation surgery at our center \~10 years ago. In this study, we calculated the incidence of intestinal perforation in adult liver transplant patients and investigated the high risk factors for intestinal perforation.

Materials and methods
=====================

Patients
--------

In this retrospective study, the clinical data of patients who received liver transplantation between January 2014 and June 2016 at the Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, were collected and reviewed. The study protocol was approved by the ethics committee of Beijing Chaoyang Hospital and patients have signed an informed consent.

Surgical technique
------------------

Modified piggyback liver transplantation was performed for all patients. All the operations were performed by the same team with \>10 years of experience in liver transplantation surgery.

Pretransplantation data of the recipients, including demographics, cause of liver disease, and Child-Pugh classification, were retrieved. Perioperative data, including cold and warm ischemia time, operative time, estimated blood loss, and blood transfusion, were recorded. Type of antirejection drugs, complications after surgery, and length of hospital stay were also analyzed.

Results
=======

Patient demographic and baseline characteristics
------------------------------------------------

During the review period, 149 patients underwent liver transplant surgery. Four (2.7%) patients including three males and one female with a median age of 68 years (range: 58--72 years) developed intestinal perforation on days 9--14 after liver transplantation. The demographic and baseline characteristics of these patients are shown in [Table 1](#t1-tcrm-13-675){ref-type="table"}. Of the four patients, two had hepatocellular carcinoma; and two had hepatitis B virus (HBV)-associated cirrhosis and a history of abdominal surgery.

Treatment characteristics
-------------------------

Methylprednisolone was given at an intraoperative dose of 500 mg and infused at 40 mg four times per day from postoperative day 1 (POD1) to POD4 and was tapered from POD8 to POD14 at 30 mg daily. Meanwhile, basiliximab (20 mg) was given to all four patients during the operation and at POD4. All patients received oral tacrolimus 4 mg twice daily from POD1 to maintain a plasma concentration of 6 to 8 ng/mL.

The patients developed intestinal perforations at POD7 to POD14, and the diagnosis was confirmed by laparotomy. Perforation occurred in the jejunum in one case, the terminal ileum in two cases, and the proximal transverse hepatic flexure in one case. The characteristics of the intestinal perforations in these patients are shown in [Table 2](#t2-tcrm-13-675){ref-type="table"}. All perforations were single with a mean diameter of 1.4 cm (range: 1.0--2.5 cm). The perforations were repaired by interrupted silk sutures, and drainage tubes were placed. Two patients uneventfully recovered, but intestinal perforation recurred in one patient with perforation of the jejunum and in one patient with perforation of the ileum 1 week after the repair surgery.

Laparotomy revealed a perforation within 10 cm of the original perforation in the patient with perforation of the jejunum, which had healed. The perforation was repaired. The new perforation in the patient with perforation of the ileum had severe local inflammatory response, and terminal ileum resection and ileostomy were performed. The patients were discharged after symptomatic treatment, and there was no perioperative death. The median length of hospital stay was 26 days (range: 22--32 days).

Discussion
==========

Intestinal perforation is a rare complication of liver transplantation and is even less frequent in adult liver transplant recipients than pediatric liver transplant recipients. Perforation following liver transplantation is mainly due to the use of immunosuppressive agents, leading to intestinal wall necrosis, rupture, perforation, overflow of intestinal contents to the abdominal cavity, causing abdominal infection, diffuse peritonitis, toxic shock, and even death. Typical clinical manifestations such as abdominal tenderness, fever, and leukocytosis may be obscured by the use of high-dose hormones and immunosuppressive agents, increasing the difficulty of early diagnosis of the condition. At present, the diagnosis of abdominal perforation is based on abdominal computed tomography (CT) findings, as evidenced by accumulation of significant intraperitoneal fluid and changes in the nature of intraperitoneal drainage fluid. Current literature is scant on intestinal perforations, and most are anecdotal reports. We showed here that the incidence of intestinal perforation in adult liver transplant recipients was 2.7%, which is consistent with previous studies reporting an incidence of 1% to 5.3% for adult intestinal perforations after orthotopic liver transplantation.[@b3-tcrm-13-675]--[@b6-tcrm-13-675] The reported incidence in this study is similar to that by Xiong et al[@b1-tcrm-13-675] who studied 187 Chinese adult liver transplant recipients and detected an incidence of 3.2%.

The occurrence of intestinal perforation after liver transplantation may be related to various factors including a history of previous abdominal surgery, the presence of intraperitoneal adhesions, long-term use of corticosteroids, and antirejection drugs.[@b7-tcrm-13-675]--[@b10-tcrm-13-675] In our series, two patients had a history of previous abdominal surgery, and extensive intra-abdominal adhesions were observed during surgery. The presence of abdominal adhesions increases the difficulty of surgery and significantly prolongs the operative time. In the study by Xiong et al, the majority of adults with intestinal perforation after liver transplant surgery had dense adhesions due to previous operation. Prolonged portal vein occlusion with inadequate collateral circulation may be another cause of intestinal perforation.[@b11-tcrm-13-675]--[@b13-tcrm-13-675] There are reports of portal vein occlusion time of \>65 min;[@b1-tcrm-13-675] if collateral circulation with the portal vein is not sufficient, it increases the incidence of intestinal perforation after liver transplantation. The median portal vein occlusion time in our four patients was 66.5 min, which is comparable to the median portal venous clamp time reported by other investigators.[@b1-tcrm-13-675] However, the relationship between portal vein occlusion time and occurrence of intestinal perforation remains unknown as current existing studies are small in sample size or are anecdotal case reports.

Moreover, intraoperative and postoperative high-dose corticosteroids and immunosuppressive therapy may also contribute to the onset of intestinal perforation.[@b12-tcrm-13-675]--[@b15-tcrm-13-675] Our patients received methylprednisolone, basiliximab, and tacrolimus as parts of intraoperative and perioperative management. Corticosteroids can inhibit the activities of macrophages, lymphocytes, and other inflammatory factors, but they can also stimulate gastric acid secretion and pepsin release and inhibit gastric mucus secretion, thus weakening the barrier function of the gastric mucosa. Glucocorticoids reduce the use of glucose in the body, enhance gluconeo-genesis, and promote protein catabolism, leading to delayed repair of intestinal injury. Immunosuppressive therapy may also decrease microperforation repair capacity. Basiliximab is an immunosuppressive agent used to prevent early acute organ rejection after liver transplantation. There is no report on an association of basiliximab with intestinal perforation. Although it remains a possibility that basiliximab may contribute to the occurrence of intestinal perforation, given the small size of the cohort, we cannot establish such an association.

Intestinal perforation can occur in any bowel segment.[@b16-tcrm-13-675],[@b17-tcrm-13-675] Given extensive trauma caused by liver transplant surgery, the use of glucocorticoid and immunosuppressive therapy, and the serious nature of intestinal perforation, conservative treatment has a slim chance of healing intestinal perforation. Once perforation is confirmed, laparotomy should be performed and intestinal repair undertaken. As intestinal perforation is mostly single like the patients in the current series, bowel repair can often achieve the effect of cure. For multiple perforations, if they are confined to a single bowel segment, bowel resection followed by intestinal anastomosis can be considered. Recurrence of perforation may happen, and patients, nurses, and physicians should be vigilant for symptoms and signs of intestinal perforation.

There are certain limitations in the current study. This study was a single-center experience and retrospective in nature. Furthermore, the size of the study cohort is small, preventing us from reaching a clinically meaningful conclusion. However, the limited findings of the current study show that intestinal perforation after liver transplant surgery is a serious complication, and it remains critical that prompt diagnosis be made and early treatment be initiated for patients who have a high risk for intestinal perforation, which helps to reduce comorbidities and mortality of liver transplant recipients.

Conclusion
==========

Although there was an extremely low incidence of intestinal perforation after liver transplantation, more attention should be paid to this complication. Prompt diagnosis and treatment should be delivered to patients if intestinal perforation was confirmed with the aim to reducing comorbidities and mortality.
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###### 

Patient demographic and baseline data

  No   Gender   Age (years)   History of abdominal surgery   Operation time (h)   Portal vein occlusion time (mins)   Blood loss (mL)   Infusion (mL)   Cold and warm ischemia time (h)   Pathology
  ---- -------- ------------- ------------------------------ -------------------- ----------------------------------- ----------------- --------------- --------------------------------- --------------------------
  1    M        43            No                             6                    58                                  300               0               8                                 HBV-associated cirrhosis
  2    M        56            Yes                            11                   69                                  1,000             800             9.5                               Hepatocellular carcinoma
  3    M        52            Yes                            10                   72                                  1,300             1,000           6.5                               HBV-associated cirrhosis
  4    F        49            No                             7                    67                                  500               0               7.5                               Hepatocellular carcinoma

**Abbreviations:** M, male; HBV, hepatitis B virus; F, female.

###### 

Characteristics of intestinal perforations in the study subjects

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No   Time to perforation (days)   Location of perforation               Recurred perforation   Diameter of perforation (cm)   Treatment type             Length of stay (days)
  ---- ---------------------------- ------------------------------------- ---------------------- ------------------------------ -------------------------- -----------------------
  1    11                           Terminal ileum                        No                     1.5                            Gut repair                 24

  2    14                           Jejunum                               Yes                    1.0 (first time)\              Gut repair (first time)\   28
                                                                                                 1.5 (second time)              Gut repair (second time)   

  3    9                            Terminal ileum                        Yes                    1.5 (first time)\              Gut repair (first time)\   32
                                                                                                 2.5 (second time)              Ileostomy (second time)    

  4    12                           Proximal transverse hepatic flexure   No                     1.3                            Gut repair                 22
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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